VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: In vitro and in vivo studies

Journal of Neuroimmunology

Volumn 85, Issue 2, 1998, Pages 155-167

  Martinez, Carmen ^a   Delgado, Mario ^a   Pozo, David ^b   Leceta, Javier ^a   Calvo, Juan R ^b   Ganea, Doina ^c   Gomariz, Rosa P ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Cytokine production; Macrophage; Pituitary adenylate cyclase activating polypeptide; Vasoactive intestinal peptide

Indexed keywords

ADENYLATE CYCLASE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; INTERLEUKIN 6; MESSENGER RNA; PROTEIN KINASE C; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HOMEOSTASIS; IMMUNE RESPONSE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RECEPTOR BINDING; RNA ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; CELLS, CULTURED; FEMALE; INTERLEUKIN-6; MACROPHAGES, PERITONEAL; MICE; NEUROPEPTIDES; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; RNA, MESSENGER; TRANSCRIPTION, GENETIC; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032524548     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(98)00018-6     Document Type: Article

References (65)

1. Aarden L., Lansdorp P., de Groot E. A growth factor for B cell hybridomas produced by human monocytes. Lymphokines. 10:1985;175-185.
2. Arimura A. Pituitary adenylate cyclase-activating polypeptide (PACAP): Discovery and current states of research. Regul. Pept. 37:1992;287-303.
3. Bellinger D.L., Lorton D., Brouxhon S., Felten S., Felten D.L. The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6:1996;5-27.
4. Boige N., Aminaroff B., Munk A., Laburthe M. Forskolin stimulates adenylate cyclase in human colonic crypts: Interaction with VIP. Eur. J. Pharmacol. 101:1984;111-117.
5. Bost K.L., Mason M.J. Thapsigargin and cyclopiazonic acid initiate rapid and dramatic increases of IL-6 mRNA expression and IL-6 secretion in murine peritoneal macrophages. J. Immunol. 155:1995;285-296.
6. Buscail L., Cambillau C., Seva C., Scemama J.L., DeNeef P., Robberecht P., Christophe J., Susini C., Vaysse N. Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating polypeptide. Gastroenterology. 103:1992;1002-1008.
7. Cai Y., Xin X., Shim G.-J., Mokuno Y., Uehara H., Yamada T., Agui T., Matsumoto K. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells. Endocrinology. 138:1997;2515-2520.
8. Calvo J.R., Montilla M.L., Guerrero J.M., Segura J.J. Expression of VIP receptors in mouse peritoneal macrophages: Functional and molecular characterization. J. Neuroimmunol. 50:1994;85-93.
9. Calvo J.R., Pozo D., Guerrero J.M. Functional and molecular characterization of VIP receptors and signal transduction in human and rodent immune systems. Adv. Neuroimmunol. 6:1996;39-47.
10. Cheng H.C., Kemp B.E., Pearson R.B., Smith A.J., Misconi L., Van Patten S.M., Walsh D.A. A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. J. Biol. Chem. 261:1986;989-992.
11. Chijiwa T., Mishima A., Hagiwara M., Sano M., Hayashi K., Inoue T., Naito K., Toshioka T., Hidaka H. Inhibition of forskolin-induced neurite outgrowth and protein phosphorilation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoleinsulfonamide (H89), of PC12D pheochro-mocytoma cells. J. Biol. Chem. 265:1990;5267-5272.
12. Christophe J. Type I receptors for PACAP (a neuropeptide even more important than VIP?). Biochim. Biophys. Acta. 1154:1993;183-199.
13. De la Fuente M., Delgado M., Del Rio M., Martinez C., Hernanz A., Gomariz R.P. Stimulation by vasoactive intestinal peptide (VIP) of phagocytic function of rat macrophages. Protein kinase C involvement. Regul. Pept. 48:1993;345-353.
14. De la Fuente M., Delgado M., Del Rio M., Garrido E., Leceta J., Hernanz A., Gomariz R.P. Vasoactive intestinal peptide modulation of adherence and mobility in rat peritoneal lymphocytes and macrophages. Peptides. 15:1994;1157-1163.
15. De la Fuente M., Delgado M., Gomariz R.P. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6:1996;75-91.
16. Delgado M., De la Fuente M., Martinez C., Gomariz R.P. Pituitary adenylate cyclase-activating polypeptides (PACAP27 and PACAP38) inhibit the mobility of murine thymocytes and splenic lymphocytes; comparison with VIP and implication of cAMP. J. Neuroimmunol. 62:1995;137-146.
17. Delgado M., Pozo D., Martinez C., Garrido E., Leceta J., Calvo J.R., Gomariz R.P. Characterization of gene expression of VIP and VIP1-receptor in rat peritoneal lymphocytes and macrophages. Regul. Pept. 62:1996;161-166.
18. Delgado M., Martinez C., Johnson M., Gomariz R.P., Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) in murine lymphocytes. J. Neuroimmunol. 68:1996;27-38.
19. + thymocytes from glucocorticoid-induced apoptosis. Blood. 87:1996;5152-5161.
20. Delgado M., Garrido E., De la Fuente M., Gomariz R.P. Pituitary adenylate cyclase-activating polypeptide (PACAP38) stimulates rat peritoneal macrophages functions. Peptides. 17:1996;1097-1105.
21. Ganea D. Regulatory effects of vasoactive intestinal peptide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:1996;61-74.
22. Ganea D., Sun L. VIP downregulates the expression of IL-2 but not of IFNγ from stimulated murine T lymphocytes. J. Neuroimmunol. 47:1993;147-158.
23. Garrido E., Delgado M., Martinez C., Gomariz R.P., De la Fuente M. Pituitary adenylate cyclase-activating polypeptide (PACA38) modulates lymphocyte and macrophage functions: stimulation of adherence and opposite effect on mobility. Neuropeptides. 30:1996;583-595.
24. Gaytan F., Martinez-Fuentes A.J., Gracia-Navarro F., Vaudry H., Aguilar E. Pituitary adenylate cyclase-activating polypeptide (PACAP) immunolocalization in lymphoid tissues of the rat. Cell Tissue Res. 276:1994;223-227.
25. Goldman W.E., Goldberg G., Bowman L.H., Steinmez D., Schessinger D. Mouse rDNA: sequences and evolutionary analysis of spacer and mature RNA regions. Mol. Cell. Biol. 3:1983;1488-1500.
26. Gomariz R.P., De la Fuente M., Hernanz A., Leceta J. Occurrence of vasoactive intestinal peptide (VIP) in lymphoid organs from rat and mouse. Ann. New York Acad. Sci. 650:1992;13-18.
27. Gomariz R.P., Garrido E., Leceta J., Martinez C., Abalo R., Delgado M. Gene expression of VIP receptor in rat lymphocytes. Biochem. Biophys. Res. Commun. 203:1994;1599-1604.
28. Gomariz R.P., Leceta J., Garrido E., Garrido T., Delgado M. Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes. Regul. Pept. 50:1994;177-184.
29. Gottschall P.E., Tatsuno I., Arimura A. Regulation of interleukin-6 (IL-6) secretion in primary cultured rat astrocytes: synergism of interleukin-1 (IL-1) and pituitary adenylate cyclase activating polypeptide (PACAP). Brain Res. 637:1994;197-203.
30. Greenfield E.M., Horowitz M.C., Lavish S.A. Stimulation by parathyroid hormone of interleukin-6 and leukemia inhibitory factor expression in osteoblasts is an immediate-early gene response induced by cAMP signal transduction. J. Biol. Chem. 271:1996;10984-10989.
31. Grenett H.E., Fuentes N.L., Fuller G.M. Cloning and sequence analysis of the cDNA for murine interleukin-6. Nucleic Acids Res. 18:1990;6455-6461.
32. Guerrero J.M., Prieto J.C., Elorza F.L., Ramirez R., Goberna R. Interactions of VIP with human blood mononuclear cells. Mol. Cell. Endocrinol. 21:1981;151-160.
33. Hernanz A., Tato E., De la Fuente M., De Miguel E., Arnalich F. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1β, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects. J. Neuroimmunol. 71:1996;25-30.
34. Hirano, T., Interleukin 6, In: A.W. Thonson (Ed.), The cytokine handbook, Academic Press, London, UK, 1994, pp. 145-168.
35. Inagaki N., Yoshida H., Mizuta M., Mizuno N., Fujii Y., Gonoi T., Miyazaki J.I., Seino S. Cloning and characterization of a third pituitary adenylate cyclase-activating polypeptide receptor subtype expressed in insulin-secreting cells. Proc. Natl. Acad. Sci. U.S.A. 91:1994;2679-2683.
36. Kobayashi E., Nakano H., Morimoto M., Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem. Biophys. Res. Commun. 159:1989;548-553.
37. Leceta J., Martinez C., Delgado M., Garrido E., Gomariz R.P. Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv. Neuroimmunol. 6:1996;29-36.
38. Maimone D., Cioni C., Rosa S., Macchia G., Aloisi F., Annunziata P. Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J. Neuroimmunol. 47:1993;73-81.
39. Martinez C., Delgado M., Gomariz R.P., Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J. Immunol. 156:1996;4128-4136.
40. Matsumoto H., Koyama C., Sawada T., Koike K., Hirota K., Miyake A., Arimura A., Inoue K. Pituitary folliculo-stellate-like cell line (TtT/GF) responds to novel hypophysiotropic peptide (Pituitary adenylate cyclase-activating peptide), showing increased adenosine 3′,5′-monophosphate and interleukin-6 secretion and cell proliferation. Endocrinology. 133:1993;2150-2155.
41. Miyata A., Arimura A., Dahl R.R., Minamino N., Uehara A., Jiang L., Culler M., Coy D.H. Isolation of a novel 38-residue hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem. Biophys. Res. Commun. 164:1989;567-574.
42. Moody, T.W., Zia, F., Bitar, K., Cay, D.M., PACAP (6-38) is a PACAP type I receptor antagonist on small cell lung cancer cells, in: G. Rosselin (Ed.), Vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and related regulatory peptides: from molecular biology to clinical applications, World Sci., 1994, pp. 537-544.
43. Nio D.A., Moylan R.N., Roche J.K. Modulation of T lymphocyte function by neuropeptides. J. Immunol. 150:1993;5281-5288.
44. Pozo D., Calvo J.R., Guerrero J.M. Homologous regulation of vasoactive intestinal peptide (VIP) receptors on rat peritoneal macrophages. Peptides. 16:1995;313-318.
45. Pozo D., Delgado M., Martinez C., Gomariz R.P., Guerrero J.M., Calvo J.R. Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages. Biochim. Biophys. Acta. 1359:1997;250.
46. Rawlings S.R., Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP/Vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocrine Rev. 17:1996;4-29.
47. Robberecht P., Gourlet P., DeNeef P., Woussen-Colle M.C., Vadermeers-piret M.C., Vardermeers A., Christophe J. Structural requirements for the occupancy of pituitary adenylate cyclase-activating peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP (6-38) as a potent antagonist. Eur. J. Biochem. 207:1992;239-245.
48. Said S.I., Mutt V. Potent peripheral and splanchnic vasodilator peptide from normal gut. Nature. 225:1970;863-864.
49. Segura J.J., Guerrero J.M., Goberna R., Calvo J.R. Characterization of functional receptors for vasoactive intestinal peptide (VIP) in rat peritoneal macrophages. Regul. Pept. 33:1991;133-143.
50. Segura J.J., Guerrero J.M., Goberna R., Calvo J.R. Stimulatory effect of vasoactive intestinal peptide (VIP) on cyclic AMP production in rat peritoneal macrophages. Regul. Pept. 37:1992;195-203.
51. Spangelo B.L., Isakson P.C., MacLeod R.M. Production of interleukin-6 by anterior pituitary cells is stimulated by increased intracellular adenosine 3′,5′-monophosphate and vasoactive intestinal peptide. Endocrinology. 127:1990;403-409.
52. Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P.H., Journot L. Differential signal transduction by five variants of the PACAP receptor. Nature. 365:1993;170-175.
53. Sun L., Ganea D. VIP inhibits IL-2 and IL-4 production through different mechanisms in T cells activated via TCR/CD3 complex. J. Neuroimmunol. 48:1993;59-70.
54. Taffet S.M., Greenfield A.R.L., Haddox M.K. Retinal inhibits TPA activated calcium-dependent, phospholipid-dependent protein kinase C. Biochem. Biophys. Res. Commun. 114:1983;1194-1199.
55. Tatsuno I., Somogyrai-Vigh A., Mizuno K., Gottschall P.E., Hidaka H., Arimura A. Neuropeptide regulation of interleukin-6 production from the pituitary adenylate cyclase activating polypeptide and calcitonin gene-related peptide. Endocrinology. 129:1991;1797-1804.
56. Tatsuno I., Gottschall P.E., Arimura A. Inhibition of mitogen-stimulated proliferation of murine splenocytes by a novel neuropeptide, pituitary adenylate cyclase-activating polypeptide: a comparative study with vasoactive intestinal peptide. Endocrinology. 128:1991;728-734.
57. Tatsuno I., Gottschall P.E., Koves K., Arimura A. Demonstration of specific binding sites for pituitary adenylate cyclase activating polypeptide (PACAP) in rat cultured astrocytes: molecular identification and interaction with vasoactive intestinal peptide. Peptides. 12:1991;617-621.
58. Van Oers M.H.J., Van Der Heyden A.A.P.A.M., Aarden L.A. Interleukin-6 (IL-6) in serum and urine of renal transplant recipients. Clin. Exp. Immunol. 71:1988;314-319.
59. 2-terminal amino acid sequence of a new T cell-derived lymphokyne with growth factor activity for B cell hybridomas. Proc. Natl. Acad. Sci. 83:1986;9679-9683.
60. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 8:1990;253-278.
61. 2 as a VIP antagonist. Endocrinology. 116:1985;2643-2649.
62. Wang H.Y., Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits IL-4 production in murine T cells by a post-transcriptional mechanism. J. Immunol. 156:1996;3243-3253.
63. Weissenbach J., Chernajovsky Y., Zeevi M., Shulman L., Sorecq H., Nir U., Wallach D., Perricaudet M., Tiollais P., Revel M. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc. Natl. Acad. Sci. U.S.A. 77:1980;7152-7156.
64. Wiik P., Opstad P.K., Boyum A. Binding of vasoactive intestinal peptide (VIP) by human blood monocytes: demonstration of specific binding sites. Regul. Pept. 12:1985;145-163.
65. Xin Z., Tang H., Ganea D. Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via TCR/CD3 complex. J. Neuroimmunol. 54:1994;59-68.